<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:nrc="http://nrchealth.com/20250226" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: scudder
         Document created using Broadridge PROfile 24.8.1.5246
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_2dbc617f78e8418fa0076ac59aaf3a96" contextRef="c20250226to20250226" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_136e57e40adc4c0d9c4c621abd2ef59e" contextRef="c20250226to20250226">0000070487</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="nrc-20250226.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20250226to20250226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070487</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-26</xbrli:startDate><xbrli:endDate>2025-02-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

  <div><br/>
  </div>

  <div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Washington, D.C.&#160;20549</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">____________________________________________________________________________</span>_</div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_a5df70f5504d49f097add7686b7ede0e" contextRef="c20250226to20250226">8-K</ix:nonNumeric></div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Date of Report (Date of earliest event reported):</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_853f24d18c76479f91c7a2e88140465a" contextRef="c20250226to20250226" format="ixt:date-monthname-day-year-en">February 26, 2025</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">_______________________________________________________________________________</div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_a4dd7d25f35f421eb93fcfa8d066af1a" contextRef="c20250226to20250226">National Research Corporation</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Exact name of registrant as specified in its charter)</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.67%; vertical-align: bottom; text-align: center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_2e0d67efe5ec4a948c69d32357e1ecfb" contextRef="c20250226to20250226" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
          </td>

    <td style="width: 28.66%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_7426232b93f041f88963a850effce56e" contextRef="c20250226to20250226">001-35929</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 35.67%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_2550137fa7644337ba4905b566221c82" contextRef="c20250226to20250226">47-0634000</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 35.67%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(State or other jurisdiction</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">of incorporation)</div>
          </td>

    <td style="width: 28.66%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Commission</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">File Number)</div>
          </td>

    <td style="width: 35.67%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(IRS Employer</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;&#160;Identification No.)</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 51.9%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_3b3de3ee2676475ab1599293968611d7" contextRef="c20250226to20250226">1245 Q Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_d60fffcf74f1463794ed54884c326222" contextRef="c20250226to20250226">Lincoln</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_d246b4572ffe4c89b2be493a49e3121d" contextRef="c20250226to20250226" format="ixt-sec:stateprovnameen">Nebraska</ix:nonNumeric></div>
          </td>

    <td style="width: 48.1%; vertical-align: bottom; text-align: center;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_10186eb15b8c424a86f1d26261283e85" contextRef="c20250226to20250226">68508</ix:nonNumeric><br/>
          </td>

  </tr>

  <tr>

    <td style="width: 51.9%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Address of principal executive offices)</div>
          </td>

    <td style="width: 48.1%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_db86a472e8584f95a01e84a4b3c6c08b" contextRef="c20250226to20250226">402</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_ba6871a93a8b421fa9477ce1b93ac5da" contextRef="c20250226to20250226">475-2525</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Registrant's telephone number, including area code)</div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 10.26%; vertical-align: bottom;" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_198e0671da4047cf91c5c3c629b74927" contextRef="c20250226to20250226" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 89.14%; vertical-align: bottom;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

    <td style="width: 0.61%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: bottom;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 89.14%; vertical-align: bottom;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 0.61%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: bottom;" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_ed5c1b1c26bc4fb79d50d7b3ff5f1ea3" contextRef="c20250226to20250226" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 89.14%; vertical-align: bottom;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

    <td style="width: 0.61%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: bottom;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 89.14%; vertical-align: bottom;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 0.61%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: bottom;" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_610f4f44d5ee4d67ad201753febabdae" contextRef="c20250226to20250226" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 89.14%; vertical-align: bottom;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

    <td style="width: 0.61%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: bottom;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 89.14%; vertical-align: bottom;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 0.61%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: bottom;" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_bd4f8c4b56344d91aa27f7f3bd5be924" contextRef="c20250226to20250226" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 89.14%; vertical-align: bottom;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

    <td style="width: 0.61%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: bottom;" colspan="2">&#160;</td>

    <td style="width: 89.14%; vertical-align: bottom;" colspan="3">&#160;</td>

    <td style="width: 0.61%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 99.39%; vertical-align: bottom;" colspan="5">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>
          </td>

    <td style="width: 0.61%; vertical-align: top;">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 32.37%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title of each class</div>
            </td>

    <td style="width: 34.28%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trading Symbol(s)</div>
            </td>

    <td style="width: 33.35%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 32.37%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12gTitle" id="Fact_bf3fda897c32417792e07eeeab48649f" contextRef="c20250226to20250226">$.001 Par Value Common Stock</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 34.28%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_59cf32d447c04b92bf39b524606fcfa9" contextRef="c20250226to20250226">NRC</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 33.35%; vertical-align: bottom; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The <ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_3e5dd6e2dbb54890a0b059076d11ee17" contextRef="c20250226to20250226">NASDAQ</ix:nonNumeric> Stock Market<br/>
              </div>
            </td>

  </tr>


</table>
    </div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 100%; vertical-align: bottom;" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company&#160;as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
              chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10.32%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89.68%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.32%; vertical-align: top;">&#160;</td>

    <td style="width: 89.68%; vertical-align: bottom;">
            <div style="text-align: right; text-indent: 332.8pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Emerging growth company&#160; <span style="text-indent: 0pt;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_718fd5455c2d4892a2c6c99c75a3329b" contextRef="c20250226to20250226" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10.32%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89.68%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 100%; vertical-align: top;" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
              any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; [&#160;&#160;&#160;]</div>
          </td>

  </tr>


</table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 12.03%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 5.02</div>
          </td>

    <td style="width: 87.97%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
              Certain Officers.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: top;">&#160;</td>

    <td style="width: 87.97%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: top;">&#160;</td>

    <td style="width: 87.97%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On February 26, 2025, National Research Corporation, a Delaware corporation (the &#8220;Company&#8221;), announced that the board of directors of the Company
              (the &#8220;Board&#8221;) appointed Trent Green as the Company&#8217;s Chief Executive Officer and to serve as a director, both effective June 1, 2025 (the &#8220;Effective Date&#8221;). Upon the effectiveness of Mr. Green&#8217;s appointment as Chief Executive Officer, Micheal
              D. Hays, the Company&#8217;s current Chief Executive Officer, will transition to the role of Chairman and Mr. Green will become the Company&#8217;s principal executive officer.</div>
            <div style="text-align: justify;">&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with Mr. Green&#8217;s appointment as Chief Executive Officer, the Talent and Compensation Committee approved a compensation package for
              Mr. Green, including:</div>
            <div style="text-align: justify;">&#160;</div>
            <div style="text-indent: 18pt; text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8226;</span><span class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 9pt;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">an annualized base salary of $1,250,000;</span></div>
            <div style="text-indent: 18pt; text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> <br/>
              </span></div>
            <div style="text-indent: 18pt; text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8226;</span><span class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 9pt;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">a grant of 500,000 shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;), subject to the following restrictions: (i) the Company has the option to repurchase the Shares for
                $1.00 if Mr. Green is terminated for cause or resigns without good reason prior to the third anniversary of the Effective Date, (ii) prior to the third anniversary of the Effective Date, the Shares may not be transferred, except (a) with
                the consent of the Company or (b) to certain family members, trusts for the benefit of such family members, or upon death, incompetency, or disability, and (iii) after the third anniversary of the Effective Date, only 50% of the Shares may
                be transferred during Mr. Green&#8217;s employment by the Company;</span></div>
            <div style="text-indent: 18pt; text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> <br/>
              </span></div>
            <div style="text-indent: 18pt; text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8226;</span><span class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 9pt;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">a cash signing bonus equal to the value of the Shares (based on the closing price of the Company&#8217;s common stock on the trading day prior to the Effective Date) multiplied
                by 66 2/3%; and</span></div>
            <div style="text-indent: 18pt; text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> <br/>
              </span></div>
            <div style="text-indent: 18pt; text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8226;</span><span class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 9pt;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">in the event of Mr. Green&#8217;s termination without cause or resignation with good reason after the third anniversary of the Effective Date, he will be entitled to one year of
                continued payment of his then-current annual base salary.</span></div>
            <div style="text-align: justify;">&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with Mr. Green&#8217;s appointment to the Board, the size of the Board was increased from six directors to seven directors, effective as of
              the Effective Date. The Board has not yet determined Mr. Green&#8217;s class designation.</div>
            <div style="text-align: justify;">&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">There are no arrangements or understandings between Mr. Green and any other person pursuant to which Mr. Green was appointed to serve on the Board.
              Mr. Green does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. Green will not receive any additional compensation for his service on the Board and is
              not expected to serve on any committees of the Board.</div>
            <div style="text-align: justify;">&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On February 26, 2025, the Board appointed Linda Stacy to serve as Interim Principal Financial Officer until March 31, 2025 (the &#8220;Term&#8221;). During the
              Term, Ms. Stacy will serve as the Company&#8217;s principal financial officer and principal accounting officer. Ms. Stacy will receive $150 per hour for any work performed as our Interim Principal Financial Officer.</div>
            <div style="text-align: justify;">&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ms. Stacy does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation
              S-K.</div>
            <div style="text-align: justify;">&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following is biographical information for Mr. Green and Ms. Stacy:</div>
            <div style="text-align: justify;">&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trent Green, 53, served as Chief Executive Officer of Amazon One Medical from September 2023 to February 2025 and as Chief Operating Officer from
              July 2022 through August 2023. Prior to Amazon One Medical, Mr. Green served in various roles at Legacy Health, including Senior Vice President and Chief Operating Officer between 2019 and 2022, President between 2017 and 2019, and Senior
              Vice President and Chief Strategy Officer between 2008 and 2017. From 1999 to 2008, Mr. Green was a management consultant for Tiber Group/Navigant Consulting (now Guidehouse).</div>
            <div style="text-align: justify;">&#160;</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: top;">&#160;</td>

    <td style="width: 87.97%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Linda Stacy, 54, served in various roles at the Company between 2006 and December 2024. Ms. Stacy joined the Company as Accounting Controller in
              2006, was promoted to Vice President of Finance in 2008, was promoted to Principal Accounting Officer in February 2024, and was appointed as Principal Financial Officer in May 2024. Since January 2025, Ms. Stacy has served as Vice President
              Financial Reporting and Accounting at Ameritas. From 1999 to 2006, Ms. Stacy served in various roles at MDS Pharma Services, a drug discovery and development company. Ms. Stacy started her career as a Certified Public Accountant at BKD CPAs
              &amp; Advisors.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 12.03%; vertical-align: top;">&#160;</td>

    <td style="width: 87.97%; vertical-align: top;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01</div>
          </td>

    <td style="width: 87.97%; vertical-align: bottom;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: bottom;">&#160;</td>

    <td style="width: 87.97%; vertical-align: bottom;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: bottom;">&#160;</td>

    <td style="width: 14.78%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(d)</div>
          </td>

    <td style="width: 73.19%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibits.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: bottom;">&#160;</td>

    <td style="width: 14.78%; vertical-align: bottom;">&#160;</td>

    <td style="width: 73.19%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: bottom;">&#160;</td>

    <td style="width: 14.78%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">EXHIBIT</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">NUMBER</span></div>
          </td>

    <td style="width: 73.19%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">EXHIBIT DESCRIPTION</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: bottom;">&#160;</td>

    <td style="width: 14.78%; vertical-align: bottom;">&#160;</td>

    <td style="width: 73.19%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: top;">&#160;</td>

    <td style="width: 14.78%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit991.htm">99.1</a></div>
          </td>

    <td style="width: 73.19%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">National Research Corporation press release announcing the appointment of Trent Green as Chief Executive Officer.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: top;">&#160;</td>

    <td style="width: 14.78%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
          </td>

    <td style="width: 73.19%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.03%; vertical-align: top;">&#160;</td>

    <td style="width: 87.97%; vertical-align: top;" colspan="2">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">The information in Items 5.02 and 9.01 of this report and the exhibit hereto may contain "forward-looking statements" within
              the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended.&#160; Such
              statements are made based on the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties.&#160; Actual results or events may differ from those anticipated by forward-looking statements.&#160;
              Please refer to the italicized paragraph at the end of the attached press release and various disclosures by the Company in its press releases, stockholder reports, and filings with the Securities and Exchange Commission for information
              concerning risks, uncertainties, and other factors that may affect future results.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

    <div><br/>
    </div>

    <div style="text-align: justify; text-indent: 24pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
      behalf by the undersigned hereunto duly authorized.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 38.36%; vertical-align: bottom;">&#160;</td>

    <td style="width: 61.64%; vertical-align: bottom;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">NATIONAL RESEARCH CORPORATION</div>
          </td>

  </tr>

  <tr>

    <td style="width: 38.36%; vertical-align: bottom;">&#160;</td>

    <td style="width: 13.86%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(Registrant)</div>
          </td>

    <td style="width: 47.78%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 38.36%; vertical-align: bottom;">&#160;</td>

    <td style="width: 13.86%; vertical-align: bottom;">&#160;</td>

    <td style="width: 47.78%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 38.36%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: March 4, 2025</div>
          </td>

    <td style="width: 13.86%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
          </td>

    <td style="width: 47.78%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Michael D. Hays</div>
          </td>

  </tr>

  <tr>

    <td style="width: 38.36%; vertical-align: bottom;">&#160;</td>

    <td style="width: 13.86%; vertical-align: bottom;">&#160;</td>

    <td style="width: 47.78%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Michael D. Hays</div>
          </td>

  </tr>

  <tr>

    <td style="width: 38.36%; vertical-align: bottom;">&#160;</td>

    <td style="width: 13.86%; vertical-align: bottom;">&#160;</td>

    <td style="width: 47.78%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Executive Officer</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

  </div>

  <div><br/>
  </div>

  <div><br/>
  </div>

</div>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "form8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 38640}]
{"company-data": {"conformed-name": "NATIONAL RESEARCH CORP", "cik": "0000070487", "assigned-sic": "8731", "organization-name": "08 Industrial Applications and Services", "irs-number": "470634000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35929", "film-number": "25704141"}, "business-address": {"street1": "1245 Q STREET", "city": "LINCOLN", "state": "NE", "zip": "68508", "phone": "4024752525"}, "mail-address": {"street1": "1245 Q STREET", "city": "LINCOLN", "state": "NE", "zip": "68508"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________________________
_
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 26, 2025
_______________________________________________________________________________
National Research Corporation
(Exact name of registrant as specified in its charter)
Delaware
001-35929
47-0634000
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1245 Q Street
,
Lincoln
,
Nebraska
68508
(Address of principal executive offices)
(Zip Code)
(
402
)
475-2525
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
$.001 Par Value Common Stock
NRC
The
NASDAQ
Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
              chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
              any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   [   ]
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
              Certain Officers.
On February 26, 2025, National Research Corporation, a Delaware corporation (the "Company"), announced that the board of directors of the Company
              (the "Board") appointed Trent Green as the Company's Chief Executive Officer and to serve as a director, both effective June 1, 2025 (the "Effective Date"). Upon the effectiveness of Mr. Green's appointment as Chief Executive Officer, Micheal
              D. Hays, the Company's current Chief Executive Officer, will transition to the role of Chairman and Mr. Green will become the Company's principal executive officer.
In connection with Mr. Green's appointment as Chief Executive Officer, the Talent and Compensation Committee approved a compensation package for
              Mr. Green, including:
•
an annualized base salary of $1,250,000;
•
a grant of 500,000 shares of the Company's common stock (the "Shares"), subject to the following restrictions: (i) the Company has the option to repurchase the Shares for
                $1.00 if Mr. Green is terminated for cause or resigns without good reason prior to the third anniversary of the Effective Date, (ii) prior to the third anniversary of the Effective Date, the Shares may not be transferred, except (a) with
                the consent of the Company or (b) to certain family members, trusts for the benefit of such family members, or upon death, incompetency, or disability, and (iii) after the third anniversary of the Effective Date, only 50% of the Shares may
                be transferred during Mr. Green's employment by the Company;
•
a cash signing bonus equal to the value of the Shares (based on the closing price of the Company's common stock on the trading day prior to the Effective Date) multiplied
                by 66 2/3%; and
•
in the event of Mr. Green's termination without cause or resignation with good reason after the third anniversary of the Effective Date, he will be entitled to one year of
                continued payment of his then-current annual base salary.
In connection with Mr. Green's appointment to the Board, the size of the Board was increased from six directors to seven directors, effective as of
              the Effective Date. The Board has not yet determined Mr. Green's class designation.
There are no arrangements or understandings between Mr. Green and any other person pursuant to which Mr. Green was appointed to serve on the Board.
              Mr. Green does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. Green will not receive any additional compensation for his service on the Board and is
              not expected to serve on any committees of the Board.
On February 26, 2025, the Board appointed Linda Stacy to serve as Interim Principal Financial Officer until March 31, 2025 (the "Term"). During the
              Term, Ms. Stacy will serve as the Company's principal financial officer and principal accounting officer. Ms. Stacy will receive $150 per hour for any work performed as our Interim Principal Financial Officer.
Ms. Stacy does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation
              S-K.
The following is biographical information for Mr. Green and Ms. Stacy:
Trent Green, 53, served as Chief Executive Officer of Amazon One Medical from September 2023 to February 2025 and as Chief Operating Officer from
              July 2022 through August 2023. Prior to Amazon One Medical, Mr. Green served in various roles at Legacy Health, including Senior Vice President and Chief Operating Officer between 2019 and 2022, President between 2017 and 2019, and Senior
              Vice President and Chief Strategy Officer between 2008 and 2017. From 1999 to 2008, Mr. Green was a management consultant for Tiber Group/Navigant Consulting (now Guidehouse).
Linda Stacy, 54, served in various roles at the Company between 2006 and December 2024. Ms. Stacy joined the Company as Accounting Controller in
              2006, was promoted to Vice President of Finance in 2008, was promoted to Principal Accounting Officer in February 2024, and was appointed as Principal Financial Officer in May 2024. Since January 2025, Ms. Stacy has served as Vice President
              Financial Reporting and Accounting at Ameritas. From 1999 to 2006, Ms. Stacy served in various roles at MDS Pharma Services, a drug discovery and development company. Ms. Stacy started her career as a Certified Public Accountant at BKD CPAs
              & Advisors.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
EXHIBIT
NUMBER
EXHIBIT DESCRIPTION
99.1
National Research Corporation press release announcing the appointment of Trent Green as Chief Executive Officer.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
The information in Items 5.02 and 9.01 of this report and the exhibit hereto may contain "forward-looking statements" within
              the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended.  Such
              statements are made based on the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties.  Actual results or events may differ from those anticipated by forward-looking statements. 
              Please refer to the italicized paragraph at the end of the attached press release and various disclosures by the Company in its press releases, stockholder reports, and filings with the Securities and Exchange Commission for information
              concerning risks, uncertainties, and other factors that may affect future results.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
      behalf by the undersigned hereunto duly authorized.
NATIONAL RESEARCH CORPORATION
(Registrant)
Date: March 4, 2025
By:
/s/ Michael D. Hays
Michael D. Hays
Chief Executive Officer